Novartis May Beat Ironwood Pharmaceuticals to the Punch

Novartis (NYSE:NVS) reported updated, post-hoc data for its sickle cell disease drug, crizanlizumab, in early October, and it plans to file this drug for regulatory approval before the end of next year.